factually
Index/Topics/TRAILBLAZER-ALZ Trials

TRAILBLAZER-ALZ Trials

TRAILBLAZER-ALZ clinical trials for donanemab

Fact-Checks

2 results
Jan 9, 2026
Most Viewed

Has Eli Lilly publicly disclosed trial identifiers, press releases, or peer‑reviewed data for a drug named Neurocept reported to have Phase II Alzheimer’s results?

There is no evidence in the provided reporting that Eli Lilly has publicly disclosed trial identifiers, press releases, or peer‑reviewed data for any drug called "Neurocept"; the company has, however,...

Jan 15, 2026

What are the rates and clinical consequences of ARIA in real‑world use of lecanemab and donanemab?

Real‑world reports and pooled analyses show that amyloid‑related imaging abnormalities (ARIA) are substantially more common with anti‑amyloid monoclonal antibodies than with placebo, and that lecanema...